SCHEMBL6497144

SCHEMBL6497144

COC(=O)c1ccccc1COc1ccc(NC(C)=O)c(NCc2ccc(Cl)cc2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
NCOA1 Q15788 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
NR4A2 P43354 2/20 0.41
HIF1A Q16665 2/20 0.41
NR4A1 P22736 1/20 0.41
NR4A3 Q92570 1/20 0.41
CD38 P28907 1/20 0.40
RAB9A P51151 1/20 0.39
MAOB P27338 1/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7127792 0.81 KDM4E (0.44) LMNAMRGPRX4MAPTSMN1; SMN2NR4A2
SCHEMBL6490108 0.80 NR1H2 (0.41) LMNAHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL6493102 0.77 LNPEP (0.49) LMNAHPGDMAPTALDH1A1HIF1A
SCHEMBL6489796 0.75 MAPT (0.42) LMNAHPGDMAPTALDH1A1GAA
SCHEMBL7064560 0.74 HRH3 (0.39) LMNANR4A2CD38RAB9AKDM4E
SCHEMBL6489011 0.73 SMN1; SMN2 (0.50) MAPTALDH1A1SMN1; SMN2RAB9AMAOB
SCHEMBL1826009 0.73 HTT (0.51) MAPTALDH1A1NCOA1SMN1; SMN2NCOA3
SCHEMBL6487724 0.73 HDAC1 (0.39) LMNAHPGDMAPTALDH1A1CD38
SCHEMBL7129648 0.73 LMNA (0.37) LMNANR4A2NR4A1NR4A3CD38
SCHEMBL6301593 0.72 HDAC1 (0.54) LMNAMAPTALDH1A1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD LMNA 3711/4885HPGD 2381/4885NPSR1 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.